Anhui Zhifeilong Kema Biopharmaceutical Co., Ltd.

Anhui Zhifeilong Kema Biopharmaceutical Co., Ltd. ("Zhifeilong Kema") is a high-tech enterprise specializing in the research, development, production, and sales of biological products—primarily human-use vaccines. It operates as a wholly-owned subsidiary of Chongqing Zhifei Biological Products Co., Ltd. The company has achieved commercial approval for several vaccines including those targeting tuberculosis and rabies. It also has preclinical programs such as a monkeypox vaccine nearing IND submission. The company plays an important role in China's biopharma sector with significant investment in R&D infrastructure and national-level projects.